Medicenna Therapeutics
Lead programme MDNA55 in pivotal Phase 2b clinical development for recurrent glioblastoma. For more information, see www.medicenna.com
Category
Case Studies
Lead programme MDNA55 in pivotal Phase 2b clinical development for recurrent glioblastoma. For more information, see www.medicenna.com
Case Studies